Abstract:A targeting nanoplatform LPLCH is constructed to perform a dual‐track reverse cholesterol transport strategy on atherosclerosis inhibition and degradation. LPLCH can be targeting accumulated at plaques, specifically internalized by foam cells and escape from the lysosomes. At the same time, the nanoparticles can carry the deposited cholesterol crystals and activate the cholesterol efflux, which offers a potential candidate for the efficient therapy of early‐stage atherosclerosis. As a main cause of serious cardiovascular diseases, atherosclerosis is characterized by deposited lipid and cholesterol crystals (CCs), which is considered as a great challenge to the current treatments. In this study, a dual‐track reverse cholesterol transport strategy is used to overcome the cumulative CCs in the atherosclerotic lesions via a targeting nanoplatform named as LPLCH. Endowed with the active targeting ability to the plaques, the nanoparticles can be efficiently internalized and achieve a pH‐triggered charge conversion for the escape from lysosomes. During this procedure, the liver X receptor (LXR) agonists loaded in nanoparticles are replaced by the deposited lysosomal CCs, leading to a LXR mediated up‐regulation of ATP‐binding cassette transporte ABCA1/G1 with the local CCs carrying at the same time. Thus, the cumulative CCs are removed in a dual‐track way of ABCA1/G1 mediated efflux and nanoparticle‐based carrying. The in vivo investigations indicate that LPLCH exhibits a favorable inhibition on the plaque progression and a further reversal of formed lesions when under a healthy diet. And the RNA‐sequencing suggests that the cholesterol transport also synergistically activates the anti‐inflammation effect. The dual‐track reverse cholesterol transport strategy performed by LPLCH delivers an exciting candidate for the effective inhibition and degradation of atherosclerosis.

Targeted therapy of atherosclerosis by zeolitic imidazolate framework-8 nanoparticles loaded with losartan potassium <i>via</i> simultaneous lipid-scavenging and anti-inflammation

Aiming at Early-Stage Vulnerable Plaques: A Nanoplatform with Dual-Mode Imaging and Lipid-Inflammation Integrated Regulation for Atherosclerotic Theranostics

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy

cRGD-platelet@MnO/MSN@PPARα/LXRα Nanoparticles Improve Atherosclerosis in Rats by Inhibiting Inflammation and Reducing Blood Lipid

Hyaluronic Acid-Functionalized Mesoporous Silica Nanoparticles Loading Simvastatin for Targeted Therapy of Atherosclerosis

Biomimetic ROS-responsive hyaluronic acid nanoparticles loaded with methotrexate for targeted anti-atherosclerosis

Targeting Nanoplatform for Atherosclerosis Inhibition and Degradation via a Dual‐Track Reverse Cholesterol Transport Strategy

Simultaneously Blocking ANGPTL3 and CD47 Prevents the Progression of Atherosclerosis Through Regulating Lipid Metabolism, Macrophagic Efferocytosis and Lipid Peroxidation

Intelligent response micelles with high andrographolide loading for the effective treatment of atherosclerosis

Mild low-temperature photothermal therapy demonstrated a distinctive 'hot spring' effect in the multichannel regulation of atherosclerosis instead of inducing foam cell apoptosis

Shedding New Light on Atherosclerosis Therapeutics: Nanomedicines Targeting Atherosclerotic Immune Microenvironment

Multi‐Pathway Microenvironment Regulation for Atherosclerosis Therapy Based on Beta‐Cyclodextrin/L‐Arginine/Au Nanomotors with Dual‐Mode Propulsion

Integrating Network Pharmacology and Metabolomics to Explore the Potential Mechanism of Pinolenic Acid against Atherosclerosis

Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy

Targeted nanoparticles triggered by plaque microenvironment for atherosclerosis treatment through cascade effects of reactive oxygen species scavenging and anti-inflammation

Tannic acid–poloxamer self-assembled nanoparticles for advanced atherosclerosis therapy by regulation of macrophage polarization

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment

Simultaneous Rosiglitazone Release and Low-Density Lipoprotein Removal by Chondroitin Sodium Sulfate/Cyclodextrin/Poly(acrylic acid) Composite Adsorbents for Atherosclerosis Therapy